GEO DataSets

(Submitter supplied) A gene expression profiling study was conducted in which skin biopsy samples were collected for RNA extraction and hybridization to microarrays from patients with moderate-to-severe psoriasis who participated in the phase 1, guselkumab first-in-human randomized, double-blind, placebo-controlled trial. At week 12, significant reductions in psoriasis gene expression were observed in guselkumab-treated patients.

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL13158

59 Samples

Download data: CEL

(Submitter supplied) A gene expression profiling sub-study was conducted in which skin biopsy samples (n=192) were collected for RNA extraction and hybridization to microarrays from patients with moderate-to-severe psoriasis who participated in ACCEPT, an IRB-approved Phase 3, multicenter, randomized trial. This analysis identified gene expressions significantly modulated in psoriasis lesions (LS) following ustekinumab or etanercept treatment at week 12 compared to baseline. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL570

192 Samples

Download data: CEL

(Submitter supplied) Tofacitinib is an oral Janus kinase inhibitor being investigated for psoriasis. We sought to elucidate the molecular mechanisms underlying the clinical efficacy of tofacitinib in patients with psoriasis. Twelve patients with plaque psoriasis were randomized (3:1) to receive 10 mg of tofacitinib or placebo twice daily for 12 weeks. Biopsy specimens were taken from nonlesional (baseline) and lesional (baseline, days 1 and 3, and weeks 1, 2, 4, and 12) skin. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL570

95 Samples

Download data: CEL

(Submitter supplied) To investigate the clinical and molecular effects of direct IL-17A versus selective IL-23 inhibition in patients with anti-IL-12/23 refractory psoriatic plaques.

Organism:

Homo sapiens

Type:

Expression profiling by high throughput sequencing

Platform:

GPL24676

111 Samples

Download data: MATRIX

(Submitter supplied) The interleukin (IL)-23/T-helper type 17 cell axis is a target for psoriasis. The tyrosine kinase 2 (TYK2)/Janus kinase 1 (JAK1) inhibitor, PF 06700841, will directly suppress TYK2-dependent IL-12 and IL-23 signaling and JAK1-dependent signaling in cells expressing these signaling molecules, including T cells and keratinocytes. This clinical study sought to define the inflammatory gene and cellular pathways through which PF 06700841 improves the clinical manifestations of psoriasis. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL570

105 Samples

Download data: CEL

(Submitter supplied) To explore the psoriasis phenotype and pathways involved in psoriasis, we characterized gene expression in lesional and non-lesional skin from psoriasis patients. Furthermore, we explored the effects of various doses of brodalumab on lesional skin over time.

Organism:

Homo sapiens

Type:

Expression profiling by array

Dataset:

GDS5420

Platform:

GPL570

99 Samples

Download data: CEL

Analysis of non-lesional and lesional psoriatic skins for up to 43 days following treatment with various doses of brodalumab, a human IgG2 mAb that selectively binds and blocks signaling through IL-17RA. Results provide insight into the molecular effect of blocking IL-17 signaling in psoriatic skin.

Organism:

Homo sapiens

Type:

Expression profiling by array, count, 3 agent, 4 dose, 25 individual, 4 time, 2 tissue sets

Platform:

GPL570

Series:

GSE53552

99 Samples

Download data: CEL

(Submitter supplied) In psoriasis, inflammation and epidermal hyperplasia are thought to be controlled by T cell-derived cytokines. Evidence now suggests that Th17 and Th22 cells infiltrate psoriasis lesions and by secreting IL-17 and IL-22, respectively, may drive disease-specific gene or cell responses. While studies in model systems indicate that IL-22 has a dominant pathogenic role, there is evolving evidence that IL-17 contributes to features of psoriasis. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Dataset:

GDS4458

Platform:

GPL571

30 Samples

Download data: CEL

Analysis of psoriatic skin biopsies from patients treated with 150mg of subcutaneous anti-IL-17 mAb ixekizumab (previously LY2439821) at weeks 0 and 2. IL-17 blockade resulted in a high-grade clinical improvement in psoriasis. Results provide insight into the role of IL-17 in disease pathogenesis.

Organism:

Homo sapiens

Type:

Expression profiling by array, transformed count, 2 agent, 17 individual, 2 time sets

Platform:

GPL571

Series:

GSE31652

30 Samples

Download data: CEL

(Submitter supplied) IL-17 antagonists induce impressive clinical benefit in psoriasis, but it is unknown too what extent cellular and molecular characteristics of psoriasis are suppressed by a clinically relevant dose and schedule of any IL-17 antagonist. Examine the effects the IL-17A receptor antagonist brodalumab, on the clinical and molecular characteristics of psoriasis, including IL-17 dependent gene-sets.

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL570

565 Samples

Download data: CEL

(Submitter supplied) Background: Dupilumab is an IL-4 receptor a mAb inhibiting signaling of IL-4 and IL-13, key drivers of type 2-driven inflammation, as demonstrated by its efficacy in patients with atopic/allergic diseases. Objective: This placebo-controlled, double-blind trial (NCT01979016) evaluated the efficacy, safety, and effects of dupilumab on molecular/cellular lesional and nonlesional skin phenotypes and systemic type 2 biomarkers of patients with moderate-to-severe atopic dermatitis (AD). more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL570

208 Samples

Download data: CEL

(Submitter supplied) Mild vs. severe psoriasis vulgaris is often distinguished by the Psoriasis Area and Severity Index. It is widely assumed that severe psoriasis involves higher levels of skin inflammation, but comparative molecular profiles of mild vs. severe disease have not been previously performed. In this study, we used gene arrays to phenotype North American patients with mild psoriasis vs. severe psoriasis.

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL570

33 Samples

Download data: CEL

(Submitter supplied) Scalp psoriasis shows a variable clinical spectrum and in many cases poses a great therapeutic challenge. However, it remains unknown whether the immune response of scalp psoriasis differs from understood pathomechanisms of psoriasis on other skin areas. We sought to determine the cellular and mollecular phenotype of scalp psoriasis by performing a comparative analysis of scalp vs skin using lesional and nonlesional samples from 20 Caucasian subjects with untreated moderate to severe psoriasis and significant scalp involvement, and 10 control subjects without psoriasis. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL571

45 Samples

Download data: CEL

(Submitter supplied) We studied psoriasis skin transcriptome modification induced by systemic IL-17A blockade with microarray analyses of total skin as part of a randomized placebo-controlled clinical trial (ClinicalTrial.gov identifier: NCT03131570)

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL570

69 Samples

Download data: CEL

(Submitter supplied) Durable psoriasis improvement has been reported in a subset of psoriasis patients after treatment withdrawal of biologics blocking IL-23/Type 17 T-cell (T17) autoimmune axis. However, it is not well understood if systemic blockade of the IL-23/T17 axis promotes immune tolerance in psoriasis skin. The purpose of the study was to find translational evidence that systemic IL-17A blockade promotes regulatory transcriptome modification in human psoriasis skin immune cell subsets. more...

Organism:

Homo sapiens

Type:

Expression profiling by high throughput sequencing

Platforms:

GPL18573 GPL24676

28 Samples

Download data: MTX, TSV

(Submitter supplied) Psoriasis is a worldwide chronic inflammatory skin disease. The treatment is usually designed according to its severity. In this research, RNA-seq was performed on the peripheral blood mononuclear cells (PBMCs) of 12 patients with psoriasis before and after treatment (4 week) of guselkumab.

Organism:

Homo sapiens

Type:

Expression profiling by high throughput sequencing

Platform:

GPL20795

24 Samples

Download data: TXT

(Submitter supplied) Activation of Sirtuin (silent mating type information regulation 2 homolog) 1, or SIRT1, is an unexplored therapeutic approach for treatment of inflammatory diseases. The goal of this study was to evaluate the clinical activity and tolerability of multiple doses of SRT2104, a selective activator of SIRT1, in patients with moderate to severe psoriasis after day 84 of treatment. Forty patients were randomized 4:1 to three escalating doses of SRT2104 (250, 500, 1000 mg/d SRT2104 or placebo). more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL570

22 Samples

Download data: CEL

(Submitter supplied) Single-cell RNA sequencing is transforming how we understand skin immunology, but previous human skin single-cell RNA sequencing data included only a small fraction of inflammatory cells among the overall cell population, such that functional subsets may be difficult to ascertain. We have overcome these obstacles by harvesting inflammatory cells emigrating from a half of 6 mm punch biopsy skin after 48-hour incubation in culture medium without any enzyme, and then analyzing the harvested cells with single-cell RNA sequencing. more...

Organism:

Homo sapiens

Type:

Expression profiling by high throughput sequencing

Platform:

GPL18573

23 Samples

Download data: MTX, TSV

(Submitter supplied) To understand the mechanism of disease progression in psoriasis, we defined Asian small plaque psoriasis (small psoriasis) and Asian intermediate plaque psoriasis (intermediate psoriasis) as psoriasis subtypes with limited disease progression, and compared their cellular and molecular signatures with the classic subtype of Western large plaque psoriasis (large psoriasis; GSE30999).

Organism:

Homo sapiens

Type:

Expression profiling by array; Third-party reanalysis

Platform:

GPL570

27 Samples

Download data: CEL, TXT

(Submitter supplied) Transcriptional profiling of Homo sapiens inflammatory skin diseases (whole skin biospies): Psoriasis (Pso), vs Atopic Dermatitis (AD) vs Lichen planus (Li), vs Contact Eczema (KE), vs Healthy control (KO) In recent years, different genes and proteins have been highlighted as potential biomarkers for psoriasis, one of the most common inflammatory skin diseases worldwide. However, most of these markers are not psoriasis-specific but also found in other inflammatory disorders. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL19471

150 Samples

Download data: TXT